Lung adenocarcinoma (LUAD) accounts for approximately 80% to 85% of reported lung cancer cases and develops in a sequential multistage pattern, gradually forming genetic and epigenetic alterations. Alterations in DNA methylation at CpG sites are associated with smoking-induced lung cancer, and smoking-related epigenetic alterations are involved in the modulation of multiple biological pathways. Enhancers govern gene expression across great distances by looping DNA and offering distant regulatory regions closer to their target gene promoters. Researchers recently employed Illumina HM450k DNA methylation data of patients from The Cancer Genome Atlas to determine enhancer and link enhancer ...
Lung Cancers Today
A new medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and more.
Advertisement
MK-1084 as monotherapy and in combination with pembrolizumab is effective in patients with NSCLC.
The timing of chemotherapy given to patients with SCLC does not have a statistically significant impact on OS.
The timing of chemotherapy given to patients with SCLC does not have a statistically significant effect on OS.
Lung cancer screening discussions are not happening as often as they could be among health care providers.
The postoperative comfort scale has good reliability and validity, and can be used to assess patients with lung cancer.
Just under a quarter of a million new cases of lung cancer were diagnosed in 2023, with 10-20% in non-smokers.
Preoperative ctDNA has prognostic value for determining long-term prognosis for NSCLC.
Clinical trial investigators should use a mindful approach when planning to assess HRQOL in NSCLC.
It is reasonable to upgrade ECE of tumor in lymph nodes from R0 to incomplete resection.
Worse clinical outcomes and higher risk for brain metastasis are more likely to happen in patients with metastatic NSCLC.
Advertisement
Expert Interviews on Lung Cancer
Conference Coverage
Our editors provide comprehensive coverage of ESMO Congress 2023, with a focus on lung cancer.
Our editors detail the latest data and innovations in the lung cancer space, as presented at WCLC 2023.
